Physician profile
Steven Fern
NPI 1245230358
$2,487.63
in general payments reported to CMS, 2019-2025
25 companies · $430 in 2025
The $430 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $179 · 2021: $222 · 2022: $325 · 2023: $353 · 2024: $388 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.34 | 2019-2025 | |
| Exact Sciences Corporation | $265.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kvk-Tech, INC. | $167.61 | 2019 | |
| Biogen, INC. | $152.10 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $146.16 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $137.74 | 2019-2022 | |
| Coopersurgical, INC. | $125.66 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Incyte Corporation | $114.99 | 2019 | |
| Aspira Women'S Health INC | $80.00 | 2023 | Ova1 |
| Myovant Sciences INC. | $68.13 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $66.99 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $63.21 | 2019-2023 | |
| Organon LLC | $54.53 | 2022-2024 | |
| Hologic Sales and Service, LLC | $39.44 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Evofem Biosciences, INC. | $39.19 | 2025 | Solosec, Phexx, Phexxi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicem INC. | $38.39 | 2021-2024 | |
| Millicent US INC | $27.56 | 2019-2024 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $22.64 | 2019 | |
| Baxter Healthcare | $18.78 | 2025 | Tisseel |
| Shield Therapeutics INC | $18.34 | 2023 | Accrufer |
| Pfizer INC. | $15.94 | 2023 | |
| Medtronic, INC. | $14.89 | 2023 | Venaseal |
| Avion Pharmaceuticals | $14.17 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.42 | 2021 | |
| Lupin INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.